The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global iron deficiency injectables market is expected to exhibit a CAGR of 13.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Iron deficiency injectables refer to drugs prescribed to treat iron deficiency and delivered by intravenous (IV) infusion in the body. These IV drugs offer several benefits over oral medications by ensuring faster absorption of the infused supplements. Iron deficiency injectables also help in overcoming poor adherence, non-compliance, and adverse gastrointestinal effects of oral medicines.
The market for iron deficiency injectables is currently being catalysed by the rising geriatric population and increasing prevalence of chronic conditions such as cancers, chronic kidney disease and rising number of patients undergoing dialysis. Furthermore, rising healthcare expenditures, improving diagnosis rates and strong growth from emerging markets is also expected to create a positive impact on market growth. The high prevalence of iron deficiency anemia due to the polycystic ovary syndrome (PCOS) and the rising incidences of hemodilution in pregnant women are also bolstering the demand for iron-deficiency injectables. Furthermore, the market is also being driven by the growing health concerns towards the intestinal degradation by oral iron therapies. Apart from this, the emergence of dextran-free intravenous formulations for treating iron deficiency is also augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global iron deficiency injectables market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, indication, branded/generics and distribution channel.
Breakup by Product Type:
Breakup by Indication:
Breakup by Branded/Generics:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Indication, Branded/Generics, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Turkey, Saudi Arabia|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at